Received chemotherapy or radiotherapy within  weeks prior to randomization or those who have not recovered to =< grade  adverse events (other than alopecia) due to agents administered more than  weeks earlier; herbal therapy intended as anticancer therapy must be discontinued at least  week prior to randomization; for patients who received prior immunotherapy (eg anti-CTLA-), at least five drug half-lives must have passed before the patient may enroll on this study; however, the following therapies are allowed:\r\n* Hormone-replacement therapy or oral contraceptives\r\n* Palliative radiotherapy for bone metastases >=  weeks prior to randomization
Patients who have not recovered from adverse events to < grade  (other than alopecia) due to agents administered more than  weeks earlier; however, the following therapies are allowed:\r\n* Hormone replacement therapy or oral contraceptives\r\n* Herbal therapy >  week prior to cycle , day  (herbal therapy intended as anticancer therapy must be discontinued at least  week prior to cycle , day )\r\n* Palliative radiotherapy for bone metastases >  weeks prior to cycle , day 
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (other than alopecia) due to agents administered more than  weeks earlier are excluded; however, the following therapies are allowed: \r\n* Hormone-replacement therapy or oral contraception\r\n* Herbal therapy >  days prior to randomization (herbal therapy intended as anticancer therapy must be discontinued at least  week prior to randomization)\r\n* Palliative radiotherapy for bone metastases >  days prior to randomization
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (other than alopecia) due to agents administered more than  weeks earlier; however, the following therapies are allowed:\r\n* Hormone-replacement therapy or oral contraceptives\r\n* Herbal therapy >  week prior to cycle , day  (herbal therapy intended as anticancer therapy must be discontinued at least  week prior to cycle , day )\r\n* Palliative radiotherapy for bone metastases >  weeks prior to cycle , day 
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (other than alopecia) due to agents administered more than  weeks earlier; however, the following therapies are allowed:\r\n* Hormone-replacement therapy or oral contraceptives\r\n* Herbal therapy >  week prior to cycle , day  (herbal therapy intended as anticancer therapy must be discontinued at least  week prior to cycle , day )
Anticancer therapy, including but not limited to chemotherapy, hormonal therapy, or radiotherapy, within  weeks prior to start of study treatment; however, the following are allowed:\r\n* Hormone-replacement therapy or oral contraceptives.\r\n* Herbal therapy >  week prior to start of study treatment (herbal therapy intended as anticancer therapy must be discontinued at least  week prior to start of study treatment).\r\n* Palliative radiotherapy for bone metastases >  weeks prior to start of study treatment.
Any approved anticancer therapy, including chemotherapy and hormonal therapy within  weeks prior to initiation of study treatment; however, the following are allowed: a) Hormone-replacement therapy or oral contraceptives b) Herbal therapy >  week prior to cycle , day  (herbal therapy intended as anticancer therapy must be discontinued at least  week prior to cycle , day )
Any approved anti-cancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, =<  weeks prior to first dose of study drug; however, the following are allowed:\r\n* Hormone-replacement therapy or oral contraceptives\r\n* Herbal therapy >  week prior to cycle , day  (herbal therapy intended as anti-cancer therapy must be discontinued at least  week prior to cycle , day )\r\n* Palliative radiotherapy for bone metastases >  weeks prior to cycle , day 
Any approved anticancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within  weeks prior to initiation of study treatment; however, the following are allowed:\r\n* Hormone-replacement therapy or oral contraceptives\r\n* Herbal therapy >  week prior to cycle , day  (herbal therapy intended as anticancer therapy must be discontinued at least  week prior to cycle , day )\r\n* Palliative radiotherapy for bone metastases >  weeks prior to cycle , day 
Any approved anticancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within  weeks prior to initiation of study treatment; however, the following are allowed:\r\n* Hormone-replacement therapy or oral contraceptives\r\n* Herbal therapy >  week prior to cycle , day  (herbal therapy intended as anticancer therapy must be discontinued at least  week prior to cycle , day )
Patients who have not recovered from adverse events (other than alopecia) due to agents administered more than  weeks earlier (i.e., have residual toxicities > grade ); however, the following therapies are allowed:\r\n* Hormone-replacement therapy or oral contraceptives\r\n* Herbal therapy ?  week before initiation of study treatment (herbal therapy intended as anticancer therapy must be discontinued at least  week before initiation of study treatment)\r\n* Palliative radiotherapy for bone metastases >  weeks before initiation of study treatment
Any approved anticancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within  weeks prior to initiation of study treatment; however, the following are allowed: Hormone-replacement therapy; palliative radiotherapy for bone metastases >  weeks prior to cycle , day .
Any anti-cancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within  weeks prior to initiation of study treatment, with the following exceptions:\r\n* Hormone-replacement therapy or oral contraceptives\r\n* Herbal therapy >  week before week , day  (herbal therapy intended as anti-cancer therapy must be discontinued at least  week before week , day )
Any approved anticancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within  weeks prior to initiation of study treatment; however, the following are allowed:\r\n* Hormone-replacement therapy or oral contraceptives\r\n* Herbal therapy >  week prior to cycle , day ; herbal therapy intended as anticancer therapy must also be discontinued at least  week prior to cycle , day \r\n* Palliative radiotherapy for bone metastases >  weeks prior to cycle , day 
Any approved anticancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within  weeks prior to initiation of study treatment; however, the following are allowed:\r\n* Hormone-replacement therapy or oral contraceptives\r\n* Herbal therapy >  week prior to cycle , day  (herbal therapy intended as anticancer therapy must be discontinued at least  week prior to cycle , day )
Any approved anticancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within  weeks prior to initiation of study treatment; however, the following are allowed: i. Hormone-replacement therapy or oral contraceptives ii. Herbal therapy >  week prior to Cycle , Day  (herbal therapy intended as anticancer therapy must be discontinued at least  week prior to Cycle , Day )
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (other than alopecia) due to agents administered more than  weeks earlier; however, the following therapies are allowed:\r\n* Hormone-replacement therapy or oral contraceptives\r\n* Herbal therapy >  week prior to cycle , day  (herbal therapy intended as anticancer therapy must be discontinued at least  week prior to cycle , day )
Any approved anticancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within  weeks prior to initiation of study treatment; however, the following are allowed:\r\n* Hormone-replacement therapy or oral contraceptives \r\n* Herbal therapy >  week prior to cycle , day  (herbal therapy intended as anticancer therapy must be discontinued at least  week prior to cycle , day )
Any approved anticancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within  weeks prior to initiation of study treatment; however, the following are allowed:\r\n* Hormone-replacement therapy or oral contraceptives\r\n* Herbal therapy ?  weeks prior to cycle , day  (herbal therapy intended as anticancer therapy must be discontinued at least  week prior to cycle , day )\r\n* Palliative radiotherapy for bone metastases >  weeks prior to cycle , day 
Patients who have had chemotherapy within  weeks or radiotherapy or targeted therapy  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (other than alopecia) due to agents administered more than  weeks earlier; however, the following therapies are allowed:\r\n* Hormone-replacement therapy or oral contraceptives\r\n* Herbal therapy >  week prior to cycle , day  (herbal therapy intended as anticancer therapy must be discontinued at least  week prior to cycle , day )\r\n* Palliative radiotherapy for bone metastases >  weeks prior to cycle , day 
Herbal therapy (including herbal therapy intended as anticancer therapy) <  week prior to cycle , day 
Any approved anticancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within  years prior to initiation of study treatment; however, the following are allowed:\r\n* Hormone-replacement therapy or oral contraceptives\r\n* Herbal therapy >  week prior to cycle , day  (herbal therapy intended as anticancer therapy must be discontinued at least  week prior to cycle , day )
